SAFE is an international project involving partners across South European Countries (Italy and Spain). The involved countries present one of the biggest challenges on increasing awareness related to Antimicrobial Resistance among the general population. As demonstrated in the last European survey published in 2018 a knowledge gap is still present mostly in South Europe countries but little is done at educational level to mitigate this problem.

SAFE involves academical partners (Università degli Studi di Napoli Federico II –UniNa-, Universitat de Barcelona), research partners (ISGlobal), and private enterprises (Roche Diagnostics), covering Italy and Spain, South European countries with high incidence of infections caused by resistant bacteria and lowest knowledge on this topic.


ISGlobal (Barcelona Institute for Global Health)

The Barcelona Institute for Global Health, ISGlobal, is the fruit of an innovative alliance between “la Caixa”, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health.

ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. The pivotal mechanism of its work model is the transfer of knowledge generated by scientific research to practice, a task undertaken by the institute’s Education and Policy and Global Development departments.

Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world.

Dr. Clara Ballesté: Clara is a Doctor in Biology from the University of Barcelona. She has a degree in Human Biology from the Pompeu Fabra University where she also completed a Master in Pharmaceutical and Biotechnology Industry. Before starting the doctorate, she worked for two years as a researcher at the R&D centre of the pharmaceutical laboratories Ferrer Internacional, S.A. in new antibacterial discovery projects. Subsequently, and in this same context, she worked on the search for new antituberculosis drugs at the Biosafety 3 facilities of the Animal Health Research Centre (CreSA) in Bellaterra.

In 2011 she began as a PhD student at ISGlobal in the research group “Molecular basis of antibiotic resistance” led by Dr. Jordi Vila. His research was focused on studying the relationship between resistance acquisition to the family of antibiotics called quinolones and their effect on virulence in Salmonella enterica.

She currently assumes the role of Coordinator of the Antibiotic Resistance Initiative and is Project Assistant of Dr. Vila’s research group.

Marina Tarrús: Marina Tarrús is Scientific Outreach Technician at ISGlobal. Her background includes a bachelor in Biotechnology (Molecular Biology specialization) from the Universitat de Barcelona; MSc. in Scientific, Medical and Environmental Communication; postgraduate degrees in Environment and Infrastructures for a Paradigm Shift and in Design for sustainability by Universitat Oberta de Catalunya.

Her main fields of interest are scientific outreach through arts and citizen science methodologies, sustainable development and biotechnology. With experience in scientific journalism (Vall d’Hebron Institute of Research), scientific scenography (Science and Theatre Institute) and with the role of Expert for Sustainable Development and Biotechnology (Environmental Movement of Vojvodina), she has worked in Spain, The Netherlands and the Republic of Serbia promoting projects for community engagement through citizen science and artistic outreach.

Currently she works in the Unit for Scientific Outreach and Innovation of ISGlobal as an outreach technician in projects on citizen science and participatory research as BiblioLab, Park(ing)Day Barcelona, and Researcher’s Night.

Universitat de Barcelona - Facultat de Farmàcia i Ciències de l’Alimentació

Universitat de Barcelona – Facultat de Farmàcia i Ciències de l’Alimentació

The University of Barcelona (UB) is a public university located in the city of Barcelona, Catalonia in Spain. UB is the principal centre of university research in Spain and has become a European benchmark for research activity, both in terms of the number of research programs it conducts and the excellence these have achieved.

Closely linked to the history of Barcelona and Catalonia, the UB combines the values of tradition with the fact of being an innovative institution of excellence in the teaching field. It is an urban, open, cosmopolitan university like the city of Barcelona itself.

Otherwise, the Faculty of Pharmacy and Food Sciences of the University of Barcelona is the only public university center in Catalonia where the degree in pharmacy is taught. It also teaches human nutrition and dietetics, and food science and technology. The faculty has as its identifying logo the door of Gaudí that corresponds to the door of the old Güell property.

Dr. David Miñana-Galbis: David is a Doctor in Biology from the Universitat de Barcelona (UB). He has a degree in Biological Sciences from the Universitat de València and a Master in AIDS from the UB and the Instituto de Salud Carlos III (Majadahonda, Madrid). As a PhD student, his research was focused on the phenotypic and genotypic diversity of the genus Aeromonas. He did a one year postdoctoral stay in the Universitat Autònoma de Barcelona (UAB) focused on the development of non-viral vector prototypes for gene therapy, adapted to the treatment of chronic viral diseases.

His background includes research in HIV, bacterial virulence markers, genomics, population genetics, phylogeny and taxonomy, with more than 30 publications, and an extensive experience in teaching Microbiology, Pharmaceutical and Food Biotechnology and the direction of two doctoral theses.
Currently, he is an Associate Professor in Microbiology at the UB, his research is mainly focused on genetic populations, genomics and genetic markers of Helicobacter pylori, and he is the Coordinator of the Small World Initiative (SWI) / Tiny Earth at the UB.

Denisa Cont: Denisa has a degree in Pharmacy from the University of Barcelona. During the course of the degree, she had the opportunity to participate as a SWITA in the Small World Initiative project with the aim of finding new antibiotic-producing strains and raising the awareness of the population about the alarming problem of the antimicrobial resistance. Now is also working in a 24h pharmacy as responsible of the night turn.

Roche Spain

Roche Spain

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion.

Miguel Alvarez Tejado is Doctor in Biology from the University Complutense of Madrid. His background has scientific research in the areas on Immunology and Signal transduction of angiogenesis in different Hospitals in Madrid. After a brief period of assistant professor at University Complutense of Madrid, he is now working in Roche. In Roche he developed sales, project management, innovation and marketing activities in the areas of Roche Applied Science and now Molecular Solutions, covering molecular, tissue and next generation sequencing solutions.

Francisco Aguilar Álvarez has studied business and corporate communication and advertising at EADA Business School Barcelona and IDEC-Universitat Pompeu Fabra Business School Barcelona. He has developed his entire professional career within Roche’s Diagnostics division where he has managed corporate communication from local areas in Spain to regional areas in Latin America, being part of global communication leadership teams and participating in various global digital communication projects.

Università degli Studi di Napoli Federico II – Dipartimento di Medicina Molecolare e Biotecnologie mediche

Università degli Studi di Napoli Federico II – Dipartimento di Medicina Molecolare e Biotecnologie mediche

The Department of Molecular Medicine and Medical Biotechnology (DMMBM) was established in January 2013 to implement the new organizational structure of the University of Naples Federico II. The facilities for research and teaching of the DMMBM are mostly located within the campus of the Medical School. The DMMBM carries out research activities in the following fields: structure and function of biological molecules and their involvement in the pathogenesis of human diseases, development of innovative biotechnological approaches for prevention, diagnosis and treatment of human diseases.

Teachers and researchers of the DMMBM contribute to the pre- and post- graduate teaching and training in Medicine and in Medical Biotechnology, through the organization of Bachelors, Masters, Specialization and PhD Courses. To carry out research and teaching activities, scientists and teachers of the DMMBM also contribute to the activity welfare of the University Hospital Federico II, in particular via the Departments of Integrated Activities (DAI) such as the Departments of Laboratory and Transfusional Medicine.

Maria Rosaria Catania has a Degree in Biological Sciences from University of Naples Federico II.
She is specialist in Microbiology and Virology and PhD in Microbiological Sciences from University of Campania Luigi Vanvitelli. She currently is an associate professor of Microbiology and Clinical Microbiology at Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples. She manages the Unit of Bacteriology and Micology of Azienda Ospedaliera of University Federico II. Maria Rosaria is a member of Editorial Board of: Mediators in inflammation, and BMC Infectious Diseases.

Emanuela Roscetto actually is a researcher of Microbiology and Clinical Microbiology (MED/07) at the Department of Molecular Medicine and Medical Biotechnology – University of Naples Federico II. She has: Degree in Biological Sciences from the University of Naples Federico II; PhD in Genetics and Molecular Medicine from the University of Naples Federico II; Specialization in Microbiology and Virology, from the University Federico II of Naples.

Emanuela Roscetto is a member of Editorial Board of Mediators in inflammation.

The research activities of Maria Rosaria Catania and Emanuela Roscetto mainly are focused on the anti-bacterial and anti-biofilm effects of unconventional antimicrobial strategies and on the characterization of antimicrobial resistant bacteria.